UFPTHIGH SIGNALOPPORTUNITY10-K

UFPT underwent massive expansion with revenue growing 290% to $603M while maintaining strong profitability and focusing exclusively on medical device manufacturing.

The company appears to have completed a major acquisition or business transformation, evidenced by the dramatic revenue surge alongside strategic refocusing from multi-market operations to pure-play medical device specialization. The removal of automotive market references and enhanced positioning as a "contract development and manufacturing organization" suggests successful execution of a focused growth strategy.

Comparing 2026-02-27 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

UFPT delivered exceptional financial performance with revenue surging 290% to $603M while net income exploded 317% to $68M, demonstrating strong operational leverage as gross margins remained healthy. The company strengthened its balance sheet by reducing total debt 28% to $136M while growing stockholders' equity 24% to $424M, and generated robust operating cash flow of $92M. This financial profile indicates successful scaling of operations with improving capital efficiency and reduced financial risk.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+317%
$16.4M→$68.3M

Net income grew 317% — bottom-line growth signals improving overall business health.

Gross Profit
P&L
+298.6%
$42.7M→$170.4M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+290%
$154.6M→$602.8M

Strong top-line growth of 290% — accelerating demand or successful expansion into new markets.

Interest Expense
P&L
+121.2%
$3.6M→$8.1M

Interest expense surged 121.2% — significant debt increase or rising rates materially impacting earnings.

Cash & Equivalents
Balance Sheet
+50.9%
$13.4M→$20.3M

Cash position surged 50.9% — strong cash generation or capital raise providing significant financial cushion.

Operating Cash Flow
Cash Flow
+38%
$66.6M→$91.9M

Operating cash flow surged 38% — exceptional cash generation, highest quality earnings signal.

Total Debt
Balance Sheet
-28.5%
$189.4M→$135.5M

Debt reduced 28.5% — deleveraging strengthens balance sheet and reduces financial risk.

SG&A Expense
P&L
+24.5%
$62.2M→$77.4M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Stockholders Equity
Balance Sheet
+23.7%
$342.8M→$423.9M

Equity base grew 23.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Liabilities
Balance Sheet
-19.2%
$286.2M→$231.2M

Liabilities reduced 19.2% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-03-03
ADDED
As of February 19, 2026, there were 7,713,300 shares of common stock, $0.01 par value per share, of the registrant outstanding.
BUSINESS The Company is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices.
The Company is a vital link in the medical device supply chain and a valued outsourcing partner to many of the world's top medical device manufacturers.
Our single-use and single-patient devices and components are used in a wide range of medical devices and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants.
and its wholly owned subsidiaries, as well as its share of minority-owned equity investments.
+7 more — sign up free →
REMOVED
As of February 25, 2025, there were 7,680,305 shares of common stock, $0.01 par value per share, of the registrant outstanding.
BUSINESS The Company is a designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products.
The Company believes it is an important link in the medical device supply chain and a valued outsource partner to many of the top medical device manufacturers in the world.
The Company s single-use and single-patient devices and components are used in a wide range of medical devices and packaging for minimally invasive surgery, infection prevention, robotic surgery, patient handling, orthopedic implants, wound care, wearables, and orthopedic soft goods.
The Company sells its products into distinct markets with its primary focus on the MedTech market: MedTech The global medical market is large and growing but the Company targets in specific segments where its development and manufacturing expertise and access to highly specialized materials helps customers differentiate products, improve patient outcomes, and increase their client s speed to market.
+7 more — sign up free →
MORE OPPORTUNITY SIGNALS
IRIXHIGHIRIX demonstrated a dramatic operational turnaround with revenue surging 283% wh...
2026-04-02
CSAIHIGHCSAI underwent a dramatic financial transformation with revenue growing 271% to ...
2026-03-31
PLMKWHIGHPLMKW has entered into a definitive business combination agreement with Controll...
2026-03-31
LXEOHIGHLXEO achieved significant clinical milestones with positive interim data and reg...
2026-03-30
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →